Xiaojie Lu

List of Publications by Year in descending order

71 papers	2,485 citations	201674 27 h-index	214800 47 g-index
72 all docs	72 docs citations	72 times ranked	4383 citing authors

#	Article	IF	Citations
1	T Cell Dysfunction in Cancer Immunity and Immunotherapy. Frontiers in Immunology, 2019, 10, 1719.	4.8	219
2	CRISPR-Cas9: a new and promising player in gene therapy. Journal of Medical Genetics, 2015, 52, 289-296.	3.2	150
3	Decreased levels of serum exosomal miRâ€638 predict poor prognosis in hepatocellular carcinoma. Journal of Cellular Biochemistry, 2018, 119, 4711-4716.	2.6	135
4	Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. Biomarker Research, 2020, 8, 35.	6.8	122
5	Competing endogenous RNA interplay in cancer: mechanism, methodology, and perspectives. Tumor Biology, 2015, 36, 479-488.	1.8	121
6	CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles. Molecular Therapy - Nucleic Acids, 2016, 5, e349.	5.1	120
7	Pseudogene in cancer: real functions and promising signature. Journal of Medical Genetics, 2015, 52, 17-24.	3.2	116
8	14-3-3Î¶ delivered by hepatocellular carcinoma-derived exosomes impaired anti-tumor function of tumor-infiltrating TÂlymphocytes. Cell Death and Disease, 2018, 9, 159.	6.3	96
9	Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities. Oncotarget, 2017, 8, 90521-90531.	1.8	81
10	Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591986269.	3.2	75
11	LINE-1 in cancer: multifaceted functions and potential clinical implications. Genetics in Medicine, 2016, 18, 431-439.	2.4	67
12	The long noncoding RNA NEAT1 contributes to hepatocellular carcinoma development by sponging miRâ€485 and enhancing the expression of the STAT3. Journal of Cellular Physiology, 2018, 233, 6733-6741.	4.1	56
13	NEAT1 upregulates TGFâ€Î²1 to induce hepatocellular carcinoma progression by sponging hsaâ€mirâ€139â€5p. Journal of Cellular Physiology, 2018, 233, 8578-8587.	4.1	56
14	Exosomes derived from exhausted CD8+ T cells impaired the anticancer function of normal CD8+ T cells. Journal of Medical Genetics, 2019, 56, 29-31.	3.2	55
15	Oridonin, a novel lysine acetyltransferases inhibitor, inhibits proliferation and induces apoptosis in gastric cancer cells through p53- and caspase-3-mediated mechanisms. Oncotarget, 2016, 7, 22623-22631.	1.8	52
16	Therapeutics for advanced hepatocellular carcinoma: Recent advances, current dilemma, and future directions. Journal of Cellular Physiology, 2019, 234, 12122-12132.	4.1	47
17	CRISPR-Cas9 for medical genetic screens: applications and future perspectives. Journal of Medical Genetics, 2016, 53, 91-97.	3.2	45
18	T cell exhaustion in cancer: Mechanisms and clinical implications. Journal of Cellular Biochemistry, 2018, 119, 4279-4286.	2.6	40

#	Article	IF	Citations
19	Applications and advances of CRISPR-Cas9 in cancer immunotherapy. Journal of Medical Genetics, 2019, 56, 4-9.	3.2	39
20	Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis. Journal of Cellular Physiology, 2019, 234, 1062-1070.	4.1	36
21	KrÃ¼ppel-like factors in hepatocellular carcinoma. Tumor Biology, 2015, 36, 533-541.	1.8	35
22	The LGMN pseudogene promotes tumor progression by acting as a miR-495-3p sponge in glioblastoma. Cancer Letters, 2020, 490, 111-123.	7.2	33
23	CEâ€MS based on moving reaction boundary method for urinary metabolomic analysis of gastric cancer patients. Electrophoresis, 2014, 35, 1032-1039.	2.4	31
24	Delivery of a chemotherapeutic drug using novel hollow carbon spheres for esophageal cancer treatment. International Journal of Nanomedicine, 2017, Volume 12, 6759-6769.	6.7	31
25	Therapeutic advances for patients with intermediate hepatocellular carcinoma. Journal of Cellular Physiology, 2019, 234, 12116-12121.	4.1	30
26	Gut microbiome and cancer immunotherapy. Journal of Cellular Physiology, 2020, 235, 4082-4088.	4.1	30
27	KrÃ¼ppel-like factor 2 promotes liver steatosis through upregulation of CD36. Journal of Lipid Research, 2014, 55, 32-40.	4.2	29
28	Microwave ablation of hepatocellular carcinoma as first-line treatment: long term outcomes and prognostic factors in 221 patients. Scientific Reports, 2016, 6, 32728.	3.3	29
29	Four differentially methylated gene pairs to predict the prognosis for early stage hepatocellular carcinoma patients. Journal of Cellular Physiology, 2018, 233, 6583-6590.	4.1	28
30	Hsa_circ_0070963 inhibits liver fibrosis via regulation of miR-223-3p and LEMD3. Aging, 2020, 12, 1643-1655.	3.1	28
31	New Insights into the Epithelial-to-Mesenchymal Transition in Cancer. Trends in Pharmacological Sciences, 2016, 37, 246-248.	8.7	27
32	Genetic and phenotypic difference in CD8⁺ T cell exhaustion between chronic hepatitis B infection and hepatocellular carcinoma. Journal of Medical Genetics, 2019, 56, 18-21.	3.2	26
33	Management of patients with intermediate stage hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097084.	3.2	25
34	Identification of TAF1, HNF4A, and CALM2 as potential therapeutic target genes for liver fibrosis. Journal of Cellular Physiology, 2019, 234, 9045-9051.	4.1	24
35	Functional tissue-engineered bone-like graft made of a fibrin scaffold and TG2 gene-modified EMSCs for bone defect repair. NPG Asia Materials, 2021, 13, .	7.9	24
36	Cancer immunotherapy: challenges and clinical applications. Journal of Medical Genetics, 2019, 56, 1-3.	3.2	22

#	Article	IF	Citations
37	DDX11-AS1 as potential therapy targets for human hepatocellular carcinoma. Oncotarget, 2017, 8, 44195-44202.	1.8	21
38	Safety and efficacy of TACE and gamma knife on hepatocellular carcinoma with portal vein invasion. Gut, 2016, 65, 715-716.	12.1	20
39	PPARÎ³ Antagonizes Hypoxia-Induced Activation of Hepatic Stellate Cell through Cross Mediating PI3K/AKT and cGMP/PKG Signaling. PPAR Research, 2018, 2018, 1-10.	2.4	19
40	Cancer immunotherapy: Current applications and challenges. Cancer Letters, 2020, 480, 1-3.	7.2	19
41	Assessment of liver fibrosis with the gamma-glutamyl transpeptidase to platelet ratio: a multicentre validation in patients with HBV infection. Gut, 2018, 67, 1903-1904.	12.1	18
42	KrÃ¼ppel-like factor 2 promotes cell proliferation in hepatocellular carcinoma through up-regulation of c-myc. Cancer Biology and Therapy, 2016, 17, 20-26.	3.4	17
43	The pros and cons of dying tumour cells in adaptive immune responses. Nature Reviews Immunology, 2017, 17, 591-591.	22.7	17
44	Circular RNA Circ0021205 Promotes Cholangiocarcinoma Progression Through MiR-204-5p/RAB22A Axis. Frontiers in Cell and Developmental Biology, 2021, 9, 653207.	3.7	17
45	Identification of LINC01615 as potential metastasisâ€related long noncoding RNA in hepatocellular carcinoma. Journal of Cellular Physiology, 2019, 234, 12964-12970.	4.1	16
46	Identification of copy number variation-driven genes for liver cancer via bioinformatics analysis. Oncology Reports, 2014, 32, 1845-1852.	2.6	14
47	Laparoscopic Microwave Ablation of Hepatocellular Carcinoma at Liver Surface: Technique Effectiveness and Long-Term Outcomes. Technology in Cancer Research and Treatment, 2019, 18, 153303381882433.	1.9	14
48	Discovery of a novel, potent and selective smallâ€molecule inhibitor of PDâ€1/PDâ€L1 interaction with robust in vivo antiâ€tumour efficacy. British Journal of Pharmacology, 2021, 178, 2651-2670.	5.4	13
49	Towards In Silico Prediction of the Immune-Checkpoint Blockade Response. Trends in Pharmacological Sciences, 2017, 38, 1041-1051.	8.7	12
50	Tolerability and efficacy of gamma knife radiosurgery on hepatocellular carcinoma with portal vein tumor thrombosis. Oncotarget, 2016, 7, 3614-3622.	1.8	12
51	The landscape of DNA methylation in hepatocellular carcinoma. Journal of Cellular Physiology, 2019, 234, 2631-2638.	4.1	10
52	Modeling cancer processes with CRISPR-Cas9. Trends in Biotechnology, 2015, 33, 317-319.	9.3	9
53	FibroBox: a novel noninvasive tool for predicting significant liver fibrosis and cirrhosis in HBV infected patients. Biomarker Research, 2020, 8, 48.	6.8	8
54	Lack of Aquaporin 9 Reduces Brain Angiogenesis and Exaggerates Neuronal Loss in the Hippocampus Following Intracranial Hemorrhage in Mice. Journal of Molecular Neuroscience, 2017, 61, 351-358.	2.3	7

#	Article	IF	Citations
55	DACH 1 inhibits glioma invasion and tumor growth via the Wnt/catenin pathway. OncoTargets and Therapy, 2018, Volume 11, 5853-5863.	2.0	7
56	Study on the relationship between insulin growth factor 1 and liver fibrosis in patients with chronic hepatitis C with type 2 diabetes mellitus. Journal of Cellular Biochemistry, 2018, 119, 9513-9518.	2.6	7
57	Placental Immune Tolerance and Organ Transplantation: Underlying Interconnections and Clinical Implications. Frontiers in Immunology, 2021, 12, 705950.	4.8	5
58	Stereotactic Body Radiation Therapy and Ablative Therapies for Solid Tumors: Recent Advances and Clinical Applications. Technology in Cancer Research and Treatment, 2019, 18, 153303381983072.	1.9	4
59	CRISPR in medicine: applications and challenges. Briefings in Functional Genomics, 2020, 19, 151-153.	2.7	4
60	The mechanisms and functions of circular RNAs in human diseases. Gene, 2021, 768, 145324.	2.2	4
61	Managerial Decision-making for Daily Case Allocation Scheduling and the Impact on Perioperative Quality Assurance. Translational Perioperative and Pain Medicine, 2016, 1, 20-30.	0.1	3
62	Metabolomic Profiling of Neoplastic Lesions in Mice. Methods in Enzymology, 2014, 543, 261-273.	1.0	2
63	Anticancer Opportunity Created by Loss of Tumor Suppressor Genes. Technology in Cancer Research and Treatment, 2016, 15, 729-731.	1.9	2
64	<scp>CRISPR</scp> screen: a highâ€throughput approach for cancer genetic research. Clinical Genetics, 2015, 88, 32-33.	2.0	1
65	Pseudogene: promising signature for cancer reclassification. Medical Oncology, 2015, 32, 354.	2.5	1
66	Pseudogene transcripts: Participants in tumorigenicity and promising therapeutic targets. Leukemia Research, 2016, 42, 105-106.	0.8	1
67	Circular RNA and human diseases: Basic research and translational implications. Cellular Signalling, 2021, 86, 110100.	3.6	1
68	The applications and advances of CRISPR-Cas9 in medical research. Briefings in Functional Genomics, 2017, 16, 1-3.	2.7	0
69	Pitfalls in the non-invasive assessment of liver fibrosis with eLIFT-FM VCTE algorithm. Journal of Hepatology, 2018, 68, 602-603.	3.7	0
70	Emerging challenge: dynamic solution structures of nucleic acids. Briefings in Functional Genomics, 2019, 18, 157-158.	2.7	0
71	Functional genomics in the era of cancer immunotherapy: challenges and clinical implications. Briefings in Functional Genomics, 2019, 18, 83-85.	2.7	0